Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 3
2004 6
2005 4
2006 7
2007 8
2008 16
2009 11
2010 11
2011 8
2012 13
2013 12
2014 24
2015 10
2016 10
2017 14
2018 13
2019 12
2020 20
2021 28
2022 36
2023 33
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Results by year

Filters applied: . Clear all
Page 1
Editorial Comment.
Chakiryan N, Yu A. Chakiryan N, et al. Among authors: yu a. J Urol. 2021 Sep;206(3):575-576. doi: 10.1097/JU.0000000000001786.01. Epub 2021 Jun 9. J Urol. 2021. PMID: 34105989 No abstract available.
ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors.
Hong Y, Walling BL, Kim HR, Serratelli WS, Lozada JR, Sailer CJ, Amitrano AM, Lim K, Mongre RK, Kim KD, Capece T, Lomakina EB, Reilly NS, Vo K, Gerber SA, Fan TC, Yu AL, Oakes PW, Waugh RE, Jun CD, Reagan PM, Kim M. Hong Y, et al. Among authors: yu al. Nat Immunol. 2023 Jun;24(6):1007-1019. doi: 10.1038/s41590-023-01498-x. Epub 2023 Apr 17. Nat Immunol. 2023. PMID: 37069398 Free PMC article.
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.
Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. Moses KA, et al. Among authors: yu a. J Natl Compr Canc Netw. 2023 Mar;21(3):236-246. doi: 10.6004/jnccn.2023.0014. J Natl Compr Canc Netw. 2023. PMID: 36898362
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children's Oncology Group. Yu AL, et al. N Engl J Med. 2010 Sep 30;363(14):1324-34. doi: 10.1056/NEJMoa0911123. N Engl J Med. 2010. PMID: 20879881 Free PMC article. Clinical Trial.
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Yu AL, et al. Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. doi: 10.1158/1078-0432.CCR-20-3909. Epub 2021 Jan 27. Clin Cancer Res. 2021. PMID: 33504555 Free PMC article. Clinical Trial.
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.
Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, Pan H, Wu J, Brennan R, Bishop MW, Helmig S, Stewart E, Navid F, Triplett B, Santana V, Santiago T, Hank JA, Gillies SD, Yu A, Sondel PM, Leung WH, Pappo A, Federico SM. Furman WL, et al. Among authors: yu a. J Clin Oncol. 2022 Feb 1;40(4):335-344. doi: 10.1200/JCO.21.01375. Epub 2021 Dec 6. J Clin Oncol. 2022. PMID: 34871104 Free PMC article. Clinical Trial.
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: yu al. J Clin Oncol. 2020 Jul 1;38(19):2160-2169. doi: 10.1200/JCO.20.00203. Epub 2020 Apr 28. J Clin Oncol. 2020. PMID: 32343642 Free PMC article. Clinical Trial.
Targeting glycosphingolipids for cancer immunotherapy.
Yu J, Hung JT, Wang SH, Cheng JY, Yu AL. Yu J, et al. Among authors: yu al. FEBS Lett. 2020 Nov;594(22):3602-3618. doi: 10.1002/1873-3468.13917. Epub 2020 Sep 9. FEBS Lett. 2020. PMID: 32860713 Free article. Review.
Management of post-COVID-19 olfactory dysfunction.
Wu TJ, Yu AC, Lee JT. Wu TJ, et al. Among authors: yu ac. Curr Treat Options Allergy. 2022;9(1):1-18. doi: 10.1007/s40521-021-00297-9. Epub 2022 Jan 4. Curr Treat Options Allergy. 2022. PMID: 35004126 Free PMC article. Review.
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Mody R, et al. Among authors: yu al. Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23. Lancet Oncol. 2017. PMID: 28549783 Free PMC article. Clinical Trial.
276 results